Tran Capital Management L.P. Has $39.74 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Tran Capital Management L.P. lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 19.8% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 157,146 shares of the medical research company’s stock after selling 38,700 shares during the period. IQVIA comprises approximately 4.4% of Tran Capital Management L.P.’s investment portfolio, making the stock its 9th biggest holding. Tran Capital Management L.P. owned approximately 0.09% of IQVIA worth $39,741,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. AdvisorNet Financial Inc raised its stake in IQVIA by 327.6% in the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after buying an additional 95 shares in the last quarter. Rise Advisors LLC bought a new position in IQVIA in the first quarter worth approximately $31,000. BKM Wealth Management LLC bought a new position in IQVIA in the fourth quarter worth approximately $32,000. Riverview Trust Co bought a new position in IQVIA in the first quarter worth approximately $32,000. Finally, Activest Wealth Management purchased a new position in IQVIA in the fourth quarter worth $35,000. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the topic of several analyst reports. The Goldman Sachs Group initiated coverage on shares of IQVIA in a report on Thursday, June 6th. They issued a “buy” rating and a $270.00 price target on the stock. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, June 29th. Barclays cut their price target on shares of IQVIA from $275.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, June 28th. Truist Financial cut their price target on shares of IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a report on Friday, May 3rd. Finally, Robert W. Baird dropped their price objective on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating on the stock in a report on Friday, May 3rd. Three equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $257.73.

IQVIA Stock Performance

NYSE:IQV traded down $0.66 during mid-day trading on Thursday, hitting $206.81. The company’s stock had a trading volume of 929,729 shares, compared to its average volume of 1,382,984. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.88. The stock has a market cap of $37.68 billion, a price-to-earnings ratio of 28.25, a PEG ratio of 1.89 and a beta of 1.49. The business’s fifty day moving average is $222.16 and its two-hundred day moving average is $229.72.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, beating the consensus estimate of $2.19 by $0.11. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Analysts anticipate that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.